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Summary
Objective: To investigate effects on cartilage metabolism and degeneration of injection of fibronectin fragments (Fn-fs) into rabbit knee joints.
Design: The knees of adolescent New Zealand white rabbits were intraarticularly injected with rabbit Fn-fs. Cartilage sections from both
injected and non-injected joints were treated with Safranin-O, with antibodies to the VDIPEN and NITEGE neoepitopes of degraded
aggrecan and to matrix metalloproteinase-3 (MMP-3). Proteoglycan (PG) content of cartilage was measured by a dimethylmethylene blue
assay of papain digests. PG synthesis rates were measured by 35S-sodium sulfate incorporation into explanted cartilage.
Results: In the injected joint cartilage, the Fn-fs bound cells in the upper superficial zone maximally between 6 and 24 h. By day 2, MMP-3
protein was enhanced and cartilage PG content and PG synthesis rates were reduced 40% and 70%, respectively. MMP-3 epitope and
VDIPEN and NITEGE neoepitopes were also enhanced. The PG content then increased to supernormal levels from days 14 to 35 and then
declined to normal levels by day 70, as did PG synthesis rates.
In the non-injected joint cartilage, Fn-fs were not detected. Although MMP-3 expression was enhanced between days 2 and 21 as well as
VDIPEN neoepitope, the PG content was never reduced but rather enhanced to supernormal levels from days 21 to 35. This was associated
with enhanced PG synthesis by day 7, which decreased to control levels by day 70.
Conclusions: In this cartilage degeneration model, loss of cartilage PG is followed by supernormal anabolic responses that facilitate PG
restoration. Further, the damage causes a systemic effect of enhanced PG synthesis and content in the non-injected joint cartilage. © 2001
OsteoArthritis Research Society International
Key words: Fibronectin, Cartilage, Fragments, Proteases, Damage, Proteoglycan.Received 15 November 2000; revision requested 5 January
2001; revision received 26 February 2001; accepted 2 April 2001.
Supported by the Seikagaku Corporation (Tokyo, Japan), the
Arthritis Foundation, Greater Chicago Chapter, the National
Institute of Arthritis and Musculoskeletal Diseases Specialized
Center of Research Grant AR39239-03 and the Dr Ralph and
Marian C. Falk Medical Research Trust Fund.
Address correspondence to: Gene A. Homandberg, Department
of Biochemistry, Rush Medical College at Rush-Presbyterian-St
Luke’s Medical Center, 1653 West Congress Parkway, Chicago,
Illinois 60612-3864, U.S.A. Tel: (312) 942-5468; Fax: (312) 942-
3053Introduction
We earlier reported an in vivo model of osteoarthritis (OA)
in which proteolytic fragments of fibronectin (Fn-fs) were
injected into rabbit knee joints to cause damage as
observed as a 50% loss of cartilage proteoglycan (PG)
within 7 days1. Development of this model was based on
the in vitro model in which Fn-fs added to articular cartilage
explants in culture cause a 40–60% release of cartilage
PG2, by penetrating into cartilage and surrounding
chondrocytes3. This interaction with cartilage tissue is
associated with enhanced release of catabolic cyto-
kines4,5, up-regulation of matrix metalloproteinase (MMP)673expression5–7 and temporary suppression of synthesis of
general protein and PG8,9. This results in cartilage degra-
dation in a mode involving cleavage of the physiologically
relevant ‘aggrecanase’ site10,11. The Fn-fs may operate
through a Fn receptor since antibodies to the alpha5beta1
integrin receptor also suppress PG synthesis, as do Fn-fs
(unpublished) and analog peptides of the Arg-Gly-Asp-Ser
integrin-binding sequence block activities of the Fn-fs12.
The relevance of this model is supported by observations of
Fn-fs in synovial fluids13–17 and in cartilage extracts18 of
patients with OA and rheumatoid arthritis (RA) and obser-
vations that active Fn-fs can be generated from MMP-3
action on synovial fluid Fn or of IL-1 and MMP-3 treatment
of cultured cartilage18. Major characteristics of this model
have been reviewed19.
The observation of the greatest relevance to this in vitro
model is that intra-articular injection of Fn-fs into rabbit
knee joints causes severe cartilage PG degradation1. The
utility of this model has also been demonstrated by using it
to show the efficacy of the pharmacological chondroprotec-
tive agent, high molecular weight hyaluronic acid20. Our
objectives here were to obtain additional information on the
rabbit model, to determine whether it shared certain
mechanistic parameters with those of the in vitro system, to
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All common chemicals were from Sigma Chemical
Co. (St Louis, MO, U.S.A.), unless otherwise noted. Horse-
radish peroxidase labeled goat antirabbit antibody (stock:
370 purpurogallin units/ml) was from Sigma Chemical Co.
N-hydroxysuccinimidyl (NHS)-biotin, avidin-horseradish
peroxidase (HRP) conjugate (161 units peroxidase
activity/mg protein; 7 units avidin/mg protein), nitro-blue-
tetrazolium chloride/5-bromo-4-chloro-3′-indolyphosphate
p-toludine salt (NBT/BCIP) and avidin-alkaline phos-
phatase were from Pierce Chemical Co. (Rockford, IL,
U.S.A.). Protein G-125-I(10 Ci/mg) and 35S-sulfate (43 Ci/
mg S) were from ICN Biomedicals, Inc. (Cosa Mesa, CA,
U.S.A.). Polyclonal sheep antihuman MMP-3 was gener-
ously provided by DuPont-Merck Research Laboratories
(Wilmington, DE, U.S.A.). NITEGE and VDIPEN antiserum
were kindly provided by Dr D. Visco (Merck Research
Laboratories, Rahway, NJ, U.S.A.). Cytoseal 60 was from
Stephens Scientific (Riverdale, NJ, U.S.A.).ANIMALS AND EXPERIMENTAL GROUPS
Adolescent, skeletally-immature male New Zealand
White rabbits (3–4 months of age and 3.0–3.5 kg) were
housed in cages provided in the Comparative Research
Center at The Rush-Presbyterian St. Luke’s Medical
Center. All animal-related procedures were in accord with
and approved by the Rush Institution Animal Care and Use
Committee (IACUC no. 92-075). Animals were fed Purina
Rabbit Chow and their food intake was monitored daily.
Animals were randomly assigned to experimental groups.
The positive control group (Fn-f injury) received an intra-
articular injection of Fn-f (3 M or 10 M Fn-fs in 20 mM
phosphate buffer, pH 7.4, containing 150 mM NaCl) into the
left knee with no further treatment. The contralateral right
knee joint was not injected.ISOLATION OF RABBIT FN-F
Rabbit Fn-f were isolated as described1,20 in the form of
a 1:1 molar ratio mixture of amino-terminal 29-kDa and
gelatin-binding 50-kDa Fn-f. Thus, a 3 M concentration
of injectate refers to 3 M of each of the two Fn-fs.
Immediately before injection, the mixture was dialysed
against 20 mM phosphate buffer, pH 7.4, containing
150 mM NaCl, and sterile-filtered.INJECTION PROCEDURE AND RECOVERY OF CARTILAGE
General animal related procedures have been pub-
lished1,20. Briefly, animals were anesthetized by an intra-
muscular injection of a mixture of ketamine (80 mg/cm3)
and acepromazine (2.0 mg/cm3) at a dose of 1.0 cm3
drug/1.5 kg body weight after which the left knee was
washed with 70% isopropyl alcohol. The injection was
performed by passing a 26-gauge needle attached to a
tuberculin syringe through the joint capsule lateral to the
patellar tendon under aseptic conditions. Injected jointswere moved through several flexior extension movements
at least five times to ensure equal distribution of the
injected materials throughout the joint cavity. Animals were
then placed in their pens and allowed to recover from the
anesthetic. Animals were subsequently sacrificed at time
points from 6 h to 70 days.
Both injected and non-injected knees were opened
immediately after death and examined grossly. Full-
thickness shavings of articular cartilage from the central,
habitually loaded region of the medial femoral condyle and
medial tibial plateau were obtained for analysis of PG
content. For histologic samples of the patella, including the
parapatellar synovium, samples were fixed for 1 week in
10% neutral buffered formalin containing 5% cetylpyridin-
ium chloride, decalcified in formic acid: sodium citrate (44%
formic acid: 20% sodium citrate) for 2 weeks and embed-
ded in paraffin. Microscopic sections (8 m) of the samples
were stained with Toluidine blue or Safranin-O to demon-
strate matrix PG and counterstained with fast green21 or
with hematoxylin and eosin. Sections from the left (injected)
knees and the right (untreated) control knees of each
experimental animal were stained concurrently along with
the untreated rabbit control sections to control for variations
in uptake of the stain.MORPHOLOGIC CHARACTERIZATION OF INTERACTION OF
BIOTINYLATED FN-FS WITH CARTILAGE IN VIVO
Fn-fs were biotinylated as directed by Pierce Chem. Co.
(Rockford, IL). Briefly, 74 l of a 1 mg/ml solution of NHS-
biotin in water was added to a 1.0 ml solution of 0.5 mg/ml
Fn-f in 50 mM sodium bicarbonate buffer, pH 8.5. After
30 min at room temperature, the solution was then dialysed
exhaustively against 20 mM phosphate buffer, pH 7.4, con-
taining 150 mM NaCl, for 16 h and then sterile-filtered. The
Fn-fs were injected into the left knee joints of rabbits. The
rabbits were sacrificed after 6 h, 24 h and 7 days. Articular
cartilage from the medial tibial plateau and medial femoral
condyle was removed and embedded in O.C.T. compound
and cryosectioned. The tissues on the slides were washed
with 50 mM phosphate buffer, pH 7.0, containing 150 mM
NaCl and then incubated with 0.1 U/ml avidin alkaline
phosphatase in the phosphate buffer at room temperature
for 30 min, then washed with the phosphate buffer and
incubated with NBT/BCIP substrate. Staining was allowed
to progress for 2 h. The slides were then mounted with
mounting media. Controls consisted of sections not treated
with avidin-alkaline phosphatase.WESTERN BLOT ANALYSIS OF MMP-3
Cartilage was removed from rabbits at days 2 and 7 after
injection of Fn-fs. The cartilage was subjected to extraction
with 4 M guanidine-HCl, 0.1% Triton X-100, 10 mM EDTA,
100 mM sodium acetate, pH 5.5, for 16 h at 4°C, followed
by exhaustive dialysis of the extracts against 10 mM EDTA-
water adjusted to pH 5.5. Protein concentrations were
determined by the Bio-Rad protein assay (Bio-Rad
Laboratories, Richmond, CA). An aliquot representing
10 g of protein was applied to each lane of a 10%
acrylamide SDS gel for Western blotting. Western blotting
and autoradiography were performed as described6. An
anti-MMP-3 solution was applied at 1 g/ml, followed by
125I labeled protein G at 0.3 g/ml.determine if restoration of lost PG occurred and to investi-
gate whether this model would demonstrate a systemic
effect, and thus be more physiologically relevant to human
OA.
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CHARACTERIZATION OF MMP-3 AND OF NITEGE AND VIDIPEN
NEOEPITOPE DISTRIBUTION
The patellae, including the parapatellar synovium, were
fixed for 1 week in 10% neutral buffered formalin containing
5% cetylpyridinium chloride, decalcified in formic acid:
sodium citrate (44% formic acid: 20% sodium citrate) for
2 weeks and embedded in paraffin. Microscopic sections
of 8 m were then deparaffinized and rehydrated in 10%
ethanol at 4°C overnight. To visualize matrix PG, micro-
scopic sections (8 m) of the samples were stained with
Toluidene blue or Safranin-O and fast green21.
To visualize MMP-3 epitope, unstained paraffin sections
were first incubated overnight at 4°C with 5 g/ml of sheep
anti-MMP-3 in 50 mM phosphate buffer, pH 7.0, containing
150 mM NaCl. Subsequently, a Unitect kit from Oncogene
Science (Cambridge, MA) was used to visualize the pri-
mary antibody. Biotinylated secondary mouse antibody was
added according to instructions for 1 hour at 37°C. A 100 l
volume of 5 g/ml 3,3′-diaminobenzidine, 0.3% hydrogen
peroxide in the phosphate buffer was then added to each
cartilage section. After 5 min, the substrate solution was
removed and sections washed with buffer and mounted
with coverslips using low viscosity Cytoseal 60 mounting
medium.
To visualize NITEGE and VDIPEN neoepitopes, sections
were rinsed with 50 mM Tris buffer, pH 7.5, containing
0.15 M NaCl and then incubated with chondroitinase ABC
(10 U/ml) in 0.1 M Tris, pH 8, for 90 min at 37°C. Non-
specific antibody binding sites were blocked with 1% BSA
and 1% nonimmune goat antisera in the Tris buffer for
30 min at room temperature. The sections were then incu-
bated with the primary antibody diluted 1:200 in the Tris
buffer +1% nonimmune serum at 4°C overnight and then
thoroughly rinsed in Tris buffer for 90 min. Antibody binding
was detected by adding avidin-biotinylated alkaline phos-
phatase complex in Tris buffer for 45 min at room tempera-
ture and finally with 1-Step NBT/BCIP containing 1 mM
levamisole for 3 min at room temperature. Control sections
were incubated either without primary antibody or with
pre-immune goat serum diluted 1:200 in the Tris buffer
+1% nonimmune goat serum.PG CONTENT OF CARTILAGE
PG was quantified in papain digests of cartilage as
described1 and data reported as g PG/mg wet weight
cartilage. The unpaired two-tailed Student’s t-test was used
to determine significance.RATES OF SODIUM 35S-SULFATE INCORPORATION
Sulfate incorporation was used as an index of the rate of
synthesis of PG as described8,9. Rabbit cartilage, in
1–10 mg explants, was removed from the joint, placed in
24-well culture wells in 1 ml DMEM and the media adjusted
to 10 Ci/ml sodium 35S-sulfate for 2 h, followed by a 2 h
cold chase. Cartilage was then subjected to extraction with
4 M guanidine-HCl, 0.1% Triton X-100, 10 mM EDTA,
100 mM sodium acetate, pH 5.5, for 16 h at 4°C, followed
by exhaustive dialysis of the extracts against 10 mM EDTA-
water adjusted to pH 5.5. The amount of label was
expressed as dpm/mg wet weight cartilage, converted into
% of control values and means and S.D. values reportedfrom three similar culture wells. Data were subjected to
two-sided Student’s t-test analysis where a P value <0.05
was considered significant.ResultsINJECTED FN-F PENETRATED THE CARTILAGE TISSUE WITH A
PEAK BETWEEN 6 AND 24 HOURS
In order to confirm that interaction of Fn-f with chondro-
cytes was required for the Fn-f mediated effects on carti-
lage and in order to correlate this interaction with other
parameters, a biotinylated 3 M Fn-f mixture was injected
into the left knee joints of three rabbits and its localization
within the cartilage probed. Although a transient swelling
followed each intraarticular injection, at no time were ani-
mals observed to favor the injected knee or alter their gait.
Cartilage was recovered from both knee joints of different
rabbits at 6 h, 24 h and 7 days, paraffin embedded and
sectioned and the sections were reacted with avidin-
alkaline phosphatase and substrate. Initial attempts with
avidin-horseradish peroxidase failed, perhaps because of
the lesser sensitivity of this method. We assumed the
localization we would observe in the tissue would be
specific and high affinity, since we have reported else-
where that 14C-29-kDa Fn-fs can bind and penetrate
bovine tissue and surround cells and do this in a saturate
manner in which cold Fn-fs can displace labeled Fn-fs2. In
such experiments, labeled bovine serum albumin as a
protein control did not show specific affinity for cartilage.
Preliminary data with biotinylated Fn-fs has confirmed that
Fn-fs can surround cells in bovine explants and be com-
peted with cold Fn-fs while bovine serum albumin only
binds on the superficial surface (unpublished). Thus, for
these studies here we did not include bovine serum
albumin as a protein control.
Figure 1 shows a 4× magnification of non-deparaffinized
tissue at 6 h (H-6) and 24 h (H-24). For each pair, a control
is shown on the left that corresponds to tissue not treated
with the alkaline phosphatase, but treated with substrate.
The label appears mostly in the upper zone by 6 h. By 24 h
the label is more evident in the middle to deep zones. By
day 7 (not shown), only light staining was evident. In each
case, cartilage from the non-injected side did not show
significant staining. Similar sections of cartilage 6 h after
injection were cleared of paraffin to increase the contrast.
This increase in contrast did not allow visualization of label
in cartilage from the non-injected joint (data not shown).THE FN-FS ENHANCED MMP-3 WITHIN THE CARTILAGE BY DAY 2
Extracts of cartilage recovered 2 and 7 days after injec-
tion of 3 M Fn-f from two different rabbits were subjected
to Western blotting using antihuman MMP-3. The Western
blotting was performed twice on each sample with similar
increases in MMP-3 banding seen by day 2 in all cases.
One of the blots was subjected to densitometric scanning
and the means and standard deviations of three scans
determined. Figure 2 shows that MMP-3 bands at about
43-kDa were not detectably above background in the
non-injected cartilage by day 2. However, the injected
cartilage showed a 43-kDa band at least 34 (±) 5.3 fold
above background (based on a maximal background den-
sity). By day 7, there were still no detectable bands in the
676 G. A. Homandberg et al.: Fibronectin fragment rabbit model of osteoarthritisnon-injected cartilage and the bands in the injected carti-
lage had decreased to 43 (±) 6.7% of the amount observed
at day 2. Therefore, MMP-3 peaks before day 7.Control Injected Control Non-injected
H-6
H-24
Fig. 1. Localization of bound Fn-f. A sterile biotinylated Fn-f mixture (300 l of 3 M) in 20 mM phosphate, pH 7.4, 150 mM NaCl, was injected
into the left knee joint of adolescent rabbits. The right knee served as an non-injected control. Cartilage was recovered from both knee joints
of different rabbits at 6 h, 24 h and 7 days, parrafin embedded and sectioned and the sections reacted with avidin-alkaline phosphatase
conjugate and substrate to localize biotinylated Fn-f. Shown are a 4× magnification of the 6 h (H-6) and 24 h (H-24) cartilages from the
injected and non-injected joints. The left section of each pair is control cartilage not reacted with avidin-alkaline phosphatase, but reacted
with substrate.THE FN-FS REDUCED SAFRANIN-O STAINING AND INCREASED
MMP-3 EPITOPE AND VDIPEN AND NITEGE NEOEPITOPES; THE
NON-INJECTED KNEE WAS ALSO AFFECTED
In order to visualize aggrecan loss, sections from carti-
lage of rabbit injected with 3 M Fn-fs were stained with
Safranin-O. Cartilage from non-injected right knees
showed the same level of staining at days 2, 7, 21 and 70
(data not shown) and therefore, no PG loss was evident.
Figure 3 shows in panel A, cartilage from non-injected
joints. Panels B–D show cartilage from the injected joints at
days 2, 7 and 14 days, respectively. Stain intensity was
markedly reduced at day 2 (panel B) and day 7 (panel C).
Chondrocyte resynthesis of stainable PGs was evident by
an increase in matrix Safranin-O staining 14 days after Fn-f
injection (panel D), as compared with non-injected tissue.
Twenty-eight days as well as 70 days after Fn-f injection,
Safranin-O staining of matrix PGs was near normal, control
levels (data not shown).
In order to visualize MMP-3 epitope, a polyclonal anti-
sera to human MMP-3 with broad species cross-reactivity,
was utilized22. As shown in Fig. 4, the MMP-3 epitope was
slightly enhanced by day 2 in the superficial zones of
cartilage from both non-injected rabbits (panel B) and
injected rabbits (panel C), as shown by comparison with
cartilage from non-injected rabbits at day 0 (panel A). By
day 7, the staining extended to the middle and deep zones.
On days 21 and 70 (data not shown), the MMP-3 epitope
was no longer detectable; there was no evident increase
over levels in non-injected cartilage at day 0. Thus, the
patterns in both injected and non-injected tissues at day 2
and day 7 were very similar.Analysis was performed for the VDIPEN neoepitope, at
the amino-terminal side of MMP mediated Asn341-Phe342
cleavage of aggrecan23. This neoepitope could be gener-
ated by MMP-3 as well as other MMPs. Figure 5 shows
greatly enhanced neoepitope in the injected joint cartilage
by day 2 (panel C) and at day 7 (panel E) as shown by
comparison with cartilage from control non-injected rabbits
at day 0 (panel A). We did not see enhanced neoepitope at
day 21 or day 70 (data not shown). Note that the non-
injected knee showed significant neoepitope by day 2
(panel B), which by day 7 (panel D) decreased to control
non-injected levels (panel A). The levels in the non-injected
knee remained at control levels through day 70 (data not
shown). Thus, the VDIPEN pattern is not identical to that of
MMP-3, but is consistent with an MMP-3 peak that may be
maximal by day 2 and then decreases to baseline levels.
In order to correlate the MMP directed cleavage with that
of aggrecanase, another physiologically relevant protein-
ase(s) involved in aggrecan degradation, an antiserum
raised against NITEGE, the sequence on the amino-
terminal side of the Glu373-Ala374 cleavage site in aggrecan
core protein24, was utilized. The reactivity of this antisera
has been shown to correlate with proteolysis of the inter-
globular core protein domain of aggrecan, the core protein
of aggregating PG24. Figure 6 shows that the NITEGE
neoepitope increased in cartilage from a 3 M Fn-f injected
joint by day 2 (panel C) as compared with cartilage from
control non-injected rabbits at day 0 (panel A). The pattern
was similar at day 7, but by day 21 the staining decreased
(data not shown). However, by day 70 (panel E), the
neoepitope was observed throughout the full thickness
section, in contrast to the VDIPEN neoepitope. Cartilage
from the non-injected knee joint had no detectable
neoepitope at day 2 (panel B) and only slight neoepitope by
day 21 in the deeper zone (data not shown). The
neoepitope in the non-injected knee joint spread intro the
middle zone by day 70 as shown in panel D.
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PG SYNTHESIS RATES, FOLLOWED BY INCREASES TO ABOVE
NORMAL LEVELS; THE NON-INJECTED KNEE CARTILAGE WAS
ALSO AFFECTED
Two different concentrations of Fn-fs, 3 and 10 M, were
injected in order to test the dose dependent effect on PG
content and PG synthesis (Figs 7 and 8). As shown in Fig.
7(a), injection of 3 M Fn-f caused the injected knee
cartilage to lose about 40% of the total PG by day 2
(P=0.001 vs control with two-tailed Student’s t-test). At day
7, the significance of this difference as compared to day 0
was P<0.0001. The PG content rose and by day 12 the
content was not significantly different from day 0 or the
non-injected levels. From days 14 to 70, the PG contents
were significantly greater than day 0 levels (P ranged from
0.01–0.0001). The PG content in non-injected knees
remained at day 0 levels up to day 12, and then by day 14
had increased to levels up to 20% above control levels (P
ranged from 0.03–0.0001).
The PG synthesis rates in the injected cartilage
decreased by day 2 to 31% of values at day 0 (P=0.0001),
but at days 14 and 28, increased to 145 and 167%
(P=0.011, 0.005, respectively), of the control value at day 0
as shown in Fig. 7(b). By day 70, the PG synthesis rates
had returned to normal levels.Figure 8 shows the effect of a higher concentration of
10 M Fn-f. Note that the PG content in both knees
decreased at the same rate to 45% loss of PG within 2 days
(P=0.006) and returned to day 0 levels only at about day 25
as compared to day 12 for a 3 M Fn-f injection. PG
synthesis rates followed the same trend as with the 3 M
Fn-f injection. The rates increased to normal values in the
injected cartilage by day 10 similar to that observed with
3 M, while the rates in the non-injected cartilage increased
to 151% (P=0.003) compared to control at day 0.66
C F
2
C F
7
97
116
Fig. 2. Identification of MMP-3 in cartilage extracts by Western
blotting. Cartilage slices were recovered from the noninjected (C)
and injected (F) joints at day 2 and day 7. Slices were then
subjected to extraction with 4 M guanidine-HCl, 0.1% Triton X-100,
10 mM EDTA, 100 mM sodium acetate, pH 5.5, for 16 h at 4°C,
followed by exhaustive dialysis of the extracts against 10 mM
EDTA-water adjusted to pH 5.5. An aliquot representing 10 g of
protein was applied to each lane of a 10% acrylamide SDS gels for
Western blotting. The blot was reacted with 1 g/ml anti-MMP-3
solution, followed by reaction with 0.3 g/ml 125I labeled protein G,
and autoradiography of the blot. The numbers at bottom corre-
spond to rabbits at 2 days and 7 days after injection.Discussion
Our objectives were to characterize further our earlier
described animal model of cartilage injury in order to
investigate similarities with the in vitro model of Fn-f-
mediated injury. We attempted first to determine if the Fn-fs
penetrated cartilage tissue in order to confirm that chondro-
cytes had an active role in initiating their own self destruc-
tion in this Fn-f model, as would be suggested from our in
vitro work. We found that the injected Fn-fs bound through-
out the full thickness of the cartilage, similar to that
observed with cartilage cultured in vitro2,25. The injected
Fn-f were first detected on the surface and upper zones of
the cartilage from the injected joint but later were observed
associated with chondrocytes in the middle and upper
zones. Subsequently the Fn-fs were not detected by day 7.
Therefore, the kinetics of deposition of the Fn-fs within the
cartilage tissue correlated with the kinetics of cartilage
damage, as discussed below. In this study, although other
data suggested a systemic effect in which the Fn-f might be
the systemic mediator, we were unable to detect Fn-f in the
non-injected joint, perhaps due to lack of sensitivity of our
method.
We expected that the Fn-fs would enhance levels
of MMPs. We focused on MMP-3 because of our earlier
work identifying the role of MMP-3 in this model2,4,6,7,9.
However, we have also found that other MMP proteins or
MMP activities are upregulated by Fn-fs in bovine and
human explants, including MMP-1. MMP-2 and MMP-
93,6,7,8 and ‘aggrecanase’ activity (generation of NITEGE
neoepitopes)10. Thus, the PG degradation and matrix
damage described here may be due to a mixture of these
enzymes.
The injection elevated MMP-3 levels within the cartilage
maximally by day 2 followed by a decrease by day 7. These
data are consistent with maximal depletion of PG occurring
by day 2 and suggests a pulse-like damage, similar to that
reported for in vitro cultures of human cartilage5,26. In
comparison, we have reported that Fn-f treatment of cul-
tured human cartilage causes the appearance of an MMP-3
peak by 9 days with basal levels by day 14 and maximal
PG depletion by 7 days6,7.
Both the NITEGE as well as VDIPEN neoepitopes were
generated in this rabbit model, just as we reported for Fn-f-
cultured human knee cartilage27. Both neoepitopes are
generated in OA as well as rheumatoid joints28. This
observation of both neoepitopes in this rabbit model sug-
gests the physiologic relevance of this model. This model is
one of very few animal models in which these two relevant
neoepitopes have been demonstrated.
The appearance of the VDIPEN neoepitope appeared to
correlate with this pulse of damage in the injected joint.
However, in the non-injected joint, MMP-3 as well as
VDIPEN was observed, although there was no decrease in
678 G. A. Homandberg et al.: Fibronectin fragment rabbit model of osteoarthritisFig. 3. Effect of Fn-fs on PG content as shown by Safranin O staining. The left knee joint of adolescent rabbits was injected with 200 l of
sterile 3 M Fn-fs and at various times of 2, 7, 14, 28 and 70 days, the cartilage was recovered. Patellae were then fixed, decalcified and
embedded in paraffin. Microscopic sections were then deparaffinized and stained with Safranin-O and fast green20. Panel A shows cartilage
from control non-injected rabbits at day 0. Panels B–D correspond to cartilage from injected rabbits at days 2, 7 and 14, respectively.Fig. 4. Visualization of enhanced MMP-3 within the cartilage. Cartilage slices were recovered from the non-injected and injected joints at 2,
7, 21 and 70 days and fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Microscopic sections were then deparaffinized and
rehydrated in 10% ethanol at 4°C overnight. Sections were then reacted with anti-MMP-3, followed by reaction with biotinylated secondary
mouse antibody and addition of substrate, 3,3′-diaminobenzidine, hydrogen peroxide. Panel A shows cartilage from control non-injected
rabbits at day 0. The days since injection of the Fn-f are indicated in panels B–E. Each left/right pair corresponds to the non-injected (left)
and injected joints (right) from the same rabbit. Sections (not shown) that were treated with substrate, but not with antibody, showed staining
at the level of control non-injected.
Osteoarthritis and Cartilage Vol. 9, No. 8 679Fig. 5. Effect of Fn-fs on VDIPEN neoepitope. The left knee joint of adolescent rabbits was injected with 200 l of sterile 3 M Fn-fs and at
various times of 2, 7, 14, 28 and 70 days, the cartilage recovered. Sections were rinsed and then incubated with chondroitinase ABC.
Non-specific antibody binding sites were blocked with BSA and pre-immune goat anti-sera. The sections were then incubated with
anti-VDIPEN overnight, followed by reaction with avidin-biotinylated alkaline phosphatase complex and finally with substrate, 1-step
NBT/BCIP. Control sections (not shown) were incubated either without primary antibody or with pre-immune goat serum and showed no
detectable staining. Panel A shows cartilage from control non-injected rabbits at day 0. The days since injection of the Fn-f are indicated in
panels B–E. Each left/right pair corresponds to the non-injected and injected joints from the same rabbit.PG content. Thus, the non-injected knee joint may repre-
sent tissue undergoing a pre-damage phase, characterized
by enhanced degradative events as well as enhanced
anabolism, the latter of which may compensate for the
enhanced degradation of PG. This possibility is consistent
with the observation that there was enhanced PG synthesis
in the non-injected joint during this time. Thus, the appear-
ance of this neoepitope may indicate not only extensive
matrix damage but also a pre-damage phase, hyper-
anabolic phase.
The NITEGE neoepitope had a more complicated kinetic
profile. The injection caused up-regulation of NITEGE
neoepitope by day 2 which continued through day 7,
consistent with the kinetics of the MMP-3 and VDIPEN
expression and PG loss. However, the NITEGE neoepitope
reappeared by day 21 and continued to day 70, although by
that time PG loss was reversed, MMP-3 expression was
decreased and VDIPEN neoepitope had also disappeared.
Thus, the NITEGE neoepitope did not necessarily correlate
totally with matrix depleted cartilage, similar to the conclu-
sion made with the VDIPEN neoepitope above. It may be
that the cartilage entered a state of remodeling after the
restoration of PG or that a secondary phase of cartilage
damage began later. It was also interesting that the
NITEGE neoepitope also appeared in the non-injected jointby day 70. Thus, it is possible that this was due to a general
systemic effect. Nonetheless, the data suggest different
roles for the two types of aggrecan cleavages and suggest
that expression of the NITEGE neoepitope can occur in
cartilage in which the PG has been restored to normal
levels.
We can compare our results of the kinetics of appear-
ance of the NITEGE and VDIPEN neoepitopes to other
models. In murine models of zymosan-induced arthritis,
partly reversible antigen-induced arthritis and irrevers-
ible destructive collagen-induced arthritis, the NITEGE
neoepitope was present in early stages of damage in all
three models, but as the degree of damage and the
element of irreversibility of the damage increased from
the zymosan model to the collagen-induced model, the
VDIPEN neoepitope began to predominate29. Thus,
NITEGE was associated with early and milder damage
and VDIPEN with later stage, more severe damage. Since
in our model we have a very fast rate of PG loss, up to
30–40% within 2 days, we might not have been able
to observe the sequential expression of these two
neoepitopes.
The kinetic profile for the PG content and PG synthesis
rates in both the injected and non-injected joints suggested
a systemic effect, characterized by an anabolic response in
680 G. A. Homandberg et al.: Fibronectin fragment rabbit model of osteoarthritisFig. 6. Effect of Fn-fs on NITEGE neoepitope. The left knee joint of adolescent rabbits was injected with 200 l of 3 M Fn-fs and at various
times of 2, 7, 21 and 70 days, the cartilage recovered. Sections were stained as above with anti-NITEGE. Panel A shows cartilage from
control non-injected rabbits at day 0. The days since injection of the Fn-f are indicated in panels B–E. Each left/right pair corresponds to the
non-injected and injected joints from the same rabbit.the non-injected joint. The profiles also demonstrated
reparative responses in the injected knee. For example,
upon injection of the low dose of Fn-fs, the PG content of
cartilage and PG synthesis rates from the injected knee first
decreased, then slowly increased to normal values and
finally to above control levels. However, in the non-injected
knee cartilage, the PG content increased to above normal
levels after day 7 and the PG synthesis rates also appeared
to increase. Other models also show anabolic effects after
the damage. For example cytokine injection into mouse
joints causes after the initial cartilage depletion of PG, an
enhancement of PG synthesis by 1.7-fold, a decrease
in PG degradation rates to 50% of normal values and
eventual restoration of PG30.
This systemic effect appeared to be Fn-f-dose-
dependent. For example, injection of a higher dose of Fn-fs
caused a simultaneous depletion of PG in both joints. The
PG synthesis curves were also different than for the low
dose. The higher dose also suppressed PG synthesis in the
non-injected joint cartilage and both the injected and non-
injected joint cartilage samples required a longer time to
increase PG synthesis rates above control levels. Thus, the
higher concentration introduced damage characteristics in
the non-injected joint, not observed with the lower dose,
and slowed the systemic anabolic responses in both joints.
This delay in repair is similar to observations that succes-
sive intra-articular injections of catabolic cytokines resultsin an increasingly delayed return to normal PG synthesis
rates31 and normal PG degradation rates30.
One of the questions in terms of the dose dependent
systemic effect is why the lower dose enhanced an ana-
bolic response and the higher dose enhanced a catabolic
response in the non-injected knee joint. We know from our
in vitro work with bovine and human explants9,26 that as the
Fn-fs are diluted, the catabolic effects decrease and PG
synthesis becomes elevated at earlier times in culture to
above normal levels9. Thus, it takes a lower concentration
of Fn-f to enhance anabolic responses than to enhance
catabolism. Thus, with the injection of a low dose the Fn-fs
or Fn-f dependent mediators may have entered through the
circulation into the other knee joint but were diluted enough
to behave only anabolically. In contrast, the high dose may
have been high enough to allow the catabolic response to
predominate. We do not know if it would be the Fn-f that
would serve as the systemic factor, since we have been
unable to detect Fn-f in the non-injected joint, perhaps due
to lack of sensitivity of our methods. Future work will
attempt to identify the factor in this systemic response. A
systemic effect has also been reported in a model of
transection of the cranial cruciate ligament of dogs, in
which increased synthesis of hyaluronic acid was observed
in the synovium of contralateral unoperated knees32.
The model of acute articular cartilage injury shown here
has elements consistent with both moderate and severe
Osteoarthritis and Cartilage Vol. 9, No. 8 681OA within the same test animal. Specifically, injection of
Fn-fs induced severe OA-like damage but in the non-
injected knee, induced moderate OA-like effects of
enhanced PG synthesis with no depletion of PG. In com-
parison, cartilage from donors with mild and moderate OA
show gradually increasing PG synthesis rates with time,
while cartilage from donors with severe OA show low PG
synthesis rates33. Further, OA cartilage that shows initially
enhanced PG synthesis rates, later show decreases in
synthesis34. Thus, this model will allow studies of severe
traumatic OA as well as more slowly developing OA in the
same animal and also allow direct studies of the mechan-
ism of this systemic effect. Since the Fn-fs not only
enhance cartilage damage but also cause an anabolic
reparative response of the cartilage, it will also allow us to
study the mechanism(s) by which damage and repair are
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Fig. 7. Effect of 3 M Fn-fs on PG content and PG synthesis rates.
The left knee joints of adolescent rabbits were injected with 200 l
of sterile 3 M Fn-fs at day 0 and the non-injected and injected joint
cartilage assayed for PG content at various times of 2, 7, 12, 14,
21, 28, 35 and 70 days after injection (panel A). The number of
rabbits per time point is given in parentheses for days 0 (14), day
2 (4), day 7 (35), day 12 (4), day 14 (6), day 21 (3), day 28 (11) day
35 (9) and day 70 (4). Curves for both injected () and non-
injected () knee joint cartilage are shown. The cartilage from
some of the groups was transferred to explant cultures and
incorporation of 35S sulfate measured and normalized to % of
control at day 0 (panel B). For PG synthesis all values are based
on N=4.0
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rates. The left knee of adolescent rabbits was injected with 200 l
of sterile 10 M Fn-fs at day 0 and the cartilage assayed for PG
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various times of 2, 7, 10, 21 and 35 days. Curves for both injected
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The abbreviations used are: Fn, fibronectin; Fn-f,
fibronectin fragment; Fn-fs, fibronectin fragments; OA,osteoarthritis; RA, rheumatoid arthritis; MMP, matrix
metalloproteinase; MMP-3, matrix metalloproteinase-3,
also stromelysin-1; PG, proteoglycan; DMEM, Dulbecco’s
modified Eagle’s medium; DMB, dimethylmethylene blue.
